MCK Q4 2026 Earnings Call Summary

McKesson Q4 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Consolidated Revenues: $403 billion, a 12% increase year-over-year.
Adjusted Earnings Per Diluted Share: $39.11, an 18% increase; $11.69 for Q4, a 16% increase.
Adjusted Operating Profit: $6.5 billion, up 15% for the year; Q4 operating profit was $1.8 billion, a 13% increase.
Operating Cash Flow: $6.2 billion, exceeding plans; free cash flow for the year was $5.4 billion.
Shareholder Returns: $5.1 billion returned to shareholders, including $2.7 billion in share repurchases.

2. Strategic Updates and Business Highlights

Acquisitions: Successful integration of Core Ventures and PRISM Vision into oncology and multispecialty platforms, contributing to strong growth.
Separation of Medical-Surgical Solutions: Progress made towards the planned separation, including financing transactions and a minority investment from Apollo Funds valued at $13 billion.
Operational Excellence: New reporting segments introduced for better transparency; launch of a new Montreal distribution center featuring advanced automation.
Technological Investments: Continued focus on AI and automation to enhance efficiency and patient care, particularly in oncology and biopharma services.

3. Forward Guidance and Outlook

Fiscal 2027 Adjusted EPS Guidance: Expected to be between $43.80 and $44.60, representing 12% to 14% year-over-year growth.
Segment Growth Expectations:
- North American Pharmaceutical: Revenue growth of 4% to 8%.
- Oncology and Multispecialty: Revenue growth of 14.5% to 18.5%.
- Prescription Technology Solutions: Revenue growth of 2.5% to 6.5%.
Free Cash Flow: Projected at approximately $4.5 billion to $4.9 billion.

4. Bad News, Challenges, or Points of Concern

Impact of Pricing Changes: Revenue growth impacted by branded pharmaceutical price declines, particularly in the North American Pharmaceutical segment.
Weather-Related Disruptions: Although January weather did not significantly impact overall operations, it was noted as a concern during the quarter.
Biosimilar Transition Risks: Potential pressure on operating profit margins due to price reductions in oncology drugs as biosimilars enter the market.
Variable Performance in 3PL Business: Revenue fluctuations in the Prescription Technology Solutions segment due to the timing of product launches and program support.

5. Notable Q&A Insights

Oncology and Multispecialty Growth: Organic growth in the oncology segment is strong at approximately 13%, with successful integration of acquisitions contributing positively.
GLP-1 Drug Trends: Continued growth expected in the GLP-1 category, despite some quarterly revenue declines.
Operational Stability: Stable utilization trends in North American Pharmaceutical, with ongoing strength in specialty products.
Capital Deployment Strategy: Focus remains on growth, shareholder returns, and maintaining a strong credit rating, with flexibility to shift capital between M&A and repurchases as needed.

Overall, McKesson reported strong financial performance in fiscal 2026, with positive strategic developments and a solid outlook for fiscal 2027, despite facing challenges related to pricing pressures and market dynamics.

MCK — McKesson Corporation